257. Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005;45:937-943.
258. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006;55:1488-1495.
259. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-290.
260. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-1391.
261. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003;63:2215-2234.
262. Lin CC, Fang C, Benetton S, Xu GF, Yeh LT. Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother 2006;50:2926-2931.
263. Bifano M, Yan JH, Smith RA, Zhang D, Grasela DM, LaCreta F. Absence of a pharmacokinetic interaction between entecavir and adefovir. J Clin Pharmacol 2007;47:1327-1334.
264. Kearney BP, Ramanathan S, Cheng AK, Ebrahimi R, Shah J. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration. J Clin Pharmacol 2005;45:935-940.
265. Terrault NA, Tran TT, Schiff E, McGuire BM, Brown RS Jr, Tupper R, et al. Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. Liver Int 2009;29:1178-1183.
266. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-1427.
267. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525-2532.
268. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-3208.
269. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-79.
270. Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008;103:2776-2783.
271. Lok AS, Schiff E, Tsai SL, Rustgi VK, Shiffman M, Martin P, et al. Entecavir is effective irrespective of baseline ALT and HBV DNA strata for histologic and virological endpoints. [Abstract]. Gastroenterology 2005;128(Suppl 2):A742.
272. Gish R, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg(+) chronic hepatitisB (CHB) infection: observations from antiviral-na√Øve patients treated with entecavir (ETV) or lamivudine (LVD). [Abstract]. Hepatology 2006;44(Suppl 1):558A.
273. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507.
274. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625-633.
275. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
Gonzalez SA, Keeffe EB. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect

<PAGE>110